IPSC CENTURY THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, CENTURY THERAPEUTICS INC reported revenue of n/a, net income of −$34.6M and diluted EPS of −$0.17; for the fiscal year ended December 2025 revenue was $109M, up 1556.8% on the year before.

IPSC annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $109M, gross profit n/a, operating income −$17.3M, net income −$9.58M (margin -8.8%), EPS −$0.14
• Fiscal year ended Dec 2024: revenue $6.59M, gross profit n/a, operating income −$138M, net income −$127M (margin -1920.9%), EPS −$1.61
• Fiscal year ended Dec 2023: revenue $2.24M, gross profit n/a, operating income −$147M, net income −$137M (margin -6115.1%), EPS −$2.30
• Fiscal year ended Dec 2022: revenue $5.20M, gross profit n/a, operating income −$134M, net income −$131M (margin -2518.4%), EPS −$2.96
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$94.9M, net income −$95.8M (margin n/a), EPS −$2.96

IPSC quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$34.6M, EPS −$0.17
• Quarter ended Mar 31, 2026: revenue n/a, net income −$21.6M, EPS −$0.11
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$19.2M, EPS −$0.25
• Quarter ended Sep 30, 2025: revenue n/a, net income −$34.4M, EPS −$0.40
• Quarter ended Jun 30, 2025: revenue n/a, net income −$32.5M, EPS −$0.38
• Quarter ended Mar 31, 2025: revenue $109M (up 12667.7% year over year), net income $76.6M, EPS $0.89
• Quarter ended Dec 31, 2024 (from the annual report): revenue $4.17M (up 1456.7% year over year), net income −$36.1M, EPS −$0.41
• Quarter ended Sep 30, 2024: revenue $791K (up 434.5% year over year), net income −$31.2M, EPS −$0.37
• Quarter ended Jun 30, 2024: revenue $771K (up 678.8% year over year), net income −$31.2M, EPS −$0.38
• Quarter ended Mar 31, 2024: revenue $855K (down 50.3% year over year), net income −$28.1M, EPS −$0.45
• Quarter ended Dec 31, 2023 (from the annual report): revenue $268K (down 48.6% year over year), net income −$39.4M, EPS −$0.66
• Quarter ended Sep 30, 2023: revenue $148K (down 93.3% year over year), net income −$32.7M, EPS −$0.55
• Quarter ended Jun 30, 2023: revenue $99.0K (down 92.9% year over year), net income −$33.3M, EPS −$0.56
• Quarter ended Mar 31, 2023: revenue $1.72M (up 62.6% year over year), net income −$31.3M, EPS −$0.53
• Quarter ended Dec 31, 2022 (from the annual report): revenue $521K, net income −$31.7M, EPS −$1.23
• Quarter ended Sep 30, 2022: revenue $2.22M, net income −$30.7M, EPS −$0.53
• Quarter ended Jun 30, 2022: revenue $1.40M, net income −$31.0M, EPS −$0.54
• Quarter ended Mar 31, 2022: revenue $1.06M, net income −$37.5M, EPS −$0.66
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$28.2M, EPS $1.84
• Quarter ended Sep 30, 2021: revenue n/a, net income −$26.0M, EPS −$0.48

IPSC cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$104M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$110M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$88.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $14.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$89.0M, share buybacks n/a

IPSC balance sheet

• Jun 30, 2026: cash $49.6M, total assets $287M, total liabilities $54.7M, shareholders' equity $232M
• Mar 31, 2026: cash $51.0M, total assets $327M, total liabilities $61.8M, shareholders' equity $265M
• Dec 31, 2025: cash $61.9M, total assets $224M, total liabilities $64.8M, shareholders' equity $159M
• Sep 30, 2025: cash $55.5M, total assets $245M, total liabilities $68.4M, shareholders' equity $176M
• Jun 30, 2025: cash $56.9M, total assets $285M, total liabilities $74.8M, shareholders' equity $210M
• Mar 31, 2025: cash $51.9M, total assets $316M, total liabilities $75.2M, shareholders' equity $240M
• Dec 31, 2024: cash $58.4M, total assets $353M, total liabilities $192M, shareholders' equity $161M
• Sep 30, 2024: cash $52.6M, total assets $389M, total liabilities $193M, shareholders' equity $196M

What is IPSC's revenue?

CENTURY THERAPEUTICS INC reported $109M of revenue for the fiscal year ended December 2025.

Is IPSC profitable?

No. CENTURY THERAPEUTICS INC lost $110M over the last four quarters.

What is IPSC's EPS?

Diluted earnings per share over the last four quarters were −$0.93; −$0.17 in the latest quarter.

IPSC ownership and insider trades · All stocks